General MedicationsORALStandard
REPAGLINIDE
REPAGLINIDE
Standard Dose
0.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview REPAGLINIDE is listed in Drugs@FDA under application 207209 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient REPAGLINIDE Form and strength TABLET;ORAL - 0.5MG Sponsor MACLEODS PHARMS LTD Submission history Latest submission status date: 2023-03-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview REPAGLINIDE is listed in Drugs@FDA under application 207209 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient REPAGLINIDE Form and strength TABLET;ORAL - 0.5MG Sponsor MACLEODS PHARMS LTD Submission history Latest submission status date: 2023-03-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.